Quince Therapeutics, Inc. (QNCX)
| Market Cap | 32.27M -68.7% |
| Revenue (ttm) | n/a |
| Net Income | -92.48M |
| EPS | -51.81 |
| Shares Out | 1.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,465 |
| Open | 30.50 |
| Previous Close | 29.36 |
| Day's Range | 29.84 - 37.00 |
| 52-Week Range | 15.10 - 909.98 |
| Beta | 1.33 |
| Analysts | Strong Buy |
| Price Target | 75.00 (+136.37%) |
| Est. Earnings | Nov 11, 2026 |
About QNCX
Quince Therapeutics, Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company’s lead asset candidature comprises eDSP, which is in Phase 3, for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a dr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for QNCX stock is "Strong Buy." The 12-month stock price target is $75.0, which is an increase of 136.37% from the latest price.
News
Quince Therapeutics changes name to IRulya Therapeutics
Quince Therapeutics (QNCX) announced that it has changed its name to IRulya Therapeutics. IRulya will be focused on advancing LAM-001, an investigational formulation of inhaled rapamycin for multiple ...
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026 Key Management changes include new CEO, Brigette Roberts, M.D.; new CFO, John Militello, CPA; and new COO Kei...
Quince Therapeutics initiated with an Outperform at Raymond James
Raymond James initiated coverage of Quince Therapeutics (QNCX) with an Outperform rating and $72 price target Following its acquisition of Orphai Therapeutics, Quince is focused on LAM-001, an inhaled...
Quince Therapeutics Transcript: EGM 2026
Stockholders preliminarily approved the PIPE-related share issuances, increase in authorized shares, and both 2026 equity plans. The adjournment proposal was not presented after proposals 1–3 received sufficient votes.
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on October 2, 2026, providing details for shareholder voting and corporate governance matters.
Quince Therapeutics Transcript: KOL event
LAM-001, an inhaled mTOR inhibitor, demonstrated favorable safety and efficacy signals in early PH-ILD and BOS studies, with significant improvements in exercise capacity and lung function. Upcoming phase II/III trials aim to confirm these findings and address unmet needs in severe pulmonary diseases.
Quince Therapeutics Press release: KOL event
Quince Therapeutics issued a press release on September 28, 2026, disclosing material business information to investors.
Quince Therapeutics initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Seema Sheoran initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $70 price target implying 130% upside from current levels. Quince is developing LAM-001,…
Quince Therapeutics upgraded to Outperform from Market Perform at Citizens
Citizens upgraded Quince Therapeutics (QNCX) to Outperform from Market Perform with a $77 price target following the reverse merger with Orphai Therapeutics. The company is developing LAM-001, a once-...
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modify...
Quince Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
LAM-001, an inhaled mTOR inhibitor, is advancing through clinical trials for BOS, PH-ILD, and SAPH, with strong KOL support and promising early data. Key readouts are expected in Q1 2027 for BOS and Q1 2028 for PH-ILD, targeting significant unmet needs in pulmonary diseases.
Quince Therapeutics to Participate in September 2026 Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNCX), a clinical stage biopharmaceutical company focused on the development of novel, disease modify...
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on August 25, 2026, providing details for shareholder voting and corporate governance matters.
Craig-Hallum bullish on Quince Therapeutics, initiates with a Buy
As previously reported, Craig-Hallum initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $68 price target The firm notes Orphai, acquired by Quince earlier this year, is developing…
Quince Therapeutics initiated with a Buy at Craig-Hallum
Craig-Hallum initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $68 price target
Quince Therapeutics participates in a conference call with Cantor Fitzgerald
Analyst Schimmer holds a conference call with management.on August 17 at 1 pm hosted by Cantor Fitzgerald. Webcast Link
Quince Therapeutics reports Q2 EPS ($12.31), consensus ($12.39)
“This was a transformational quarter for the company with a renewed focus on a differentiated, late-stage pulmonary pipeline anchored by LAM-001 as well as a strengthened balance sheet to support…
Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin for the treatment of multiple serious, underserved pulmonary diseases, to pipeline
Quince Therapeutics Earnings release: Q2 2026
Quince Therapeutics released its Q2 2026 earnings on August 14, 2026, summarizing the period's financial results.
Quince Therapeutics Quarterly report: Q2 2026
Quince Therapeutics has published its Q2 2026 quarterly earnings report on August 14, 2026.
Quince Therapeutics Registration statement: Registration filing
Quince Therapeutics filed a registration statement on August 5, 2026, providing details about a securities offering with the SEC.
Quince Therapeutics management to meet with Oppenheimer
Meeting to be held on August 10 hosted by Oppenheimer.
Quince Therapeutics registers to sell 15.47M shares of common stock for holders
This filing relates to the offer and sale from time to time by the selling stockholders of up to 15.47M shares of common stock. The company is not selling any…
Quince Therapeutics Registration statement: Registration filing
Quince Therapeutics filed a registration statement on July 31, 2026, providing details about a securities offering with the SEC.
Quince Therapeutics Proxy statement: Proxy filing
Quince Therapeutics filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.